doi:10.1124/pr.55.1.6
Furthermore, when compared to patients not taking any of these other medications, the GLP-1 group displayed a recurrence risk of 14.5%, whereas the comparison group had a risk of 51.6%
In this article, well explore different options and help you figure out whats best for you
TT is on the advisory board for Boehringer Ingelheim, AstraZeneca, Sanofi, Novo Nordisk and Eli Lilly, and in the speakers bureau for Boehringer Ingelheim, AstraZeneca, Sanofi, Novo Nordisk, Eli Lilly, MSD, Servier and Merck
Alexander Shapsis, MD, Board-Certified Specialist in Gastroenterology and Obesity Medicine Key Takeaways: The Dangers of Protein Deficiency on Tirzepatide The Protein Crisis: Why Rapid Weight Loss Can Be Risky Tirzepatide (Mounjaro, Zepbound) is a powerful tool for weight reduction, but its effectiveness creates a unique nutritional challenge
That dual mechanism helps explain why it can be especially effective for blood sugar control and weight loss